Infectious Diseases Pharmacy Specialty Review Course for Recertification, Workbook Chapters + RECERT Assessment Package (Cert # L239222)

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in infectious diseases pharmacy.

Board certified pharmacists are eligible to receive up to 25 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed.  You are allowed only one attempt to successfully complete this assessment.

This course is not intended for those preparing to take the BPS Infectious Diseases Pharmacy Specialty Examination for Certification. To prepare for the examination, please see courses here: http://elearning.ashp.org/catalog/ID-review 

These activities are part of the ASHP and ACCP professional development program for BCIDP recertification approved by the BPS. 

After participating in these CPE activities, learners should be able to: 

Antimicrobial Stewardship
ACPE #: 0204-9999-23-966-H01-P

• Outline components of an effective stewardship program.
• Select appropriate resources; relevant accreditation, legal, regulatory, and safety requirements; and quality metrics related to infectious diseases.
• Evaluate institutional treatment policies and pathways for compliance with antimicrobial stewardship guidelines, surveillance data, and best available evidence.
• Assess the effectiveness of infection prevention strategies.
• Identify metrics for evaluating the value of infectious diseases pharmacy services. 

Upper Respiratory Tract Infections
ACPE #: 0204-9999-23-967-H01-P

• Assess pharmacotherapies for upper respiratory tract infections.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
• Recommend modifications of patient-specific treatment plans based on efficacy and adverse effects.
• Identify recommended immunizations and potential adverse effects. 

Lower Respiratory Tract Infections
ACPE #: 0204-9999-23-968-H01-P

• Assess pharmacotherapies for lower respiratory tract infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
• Recommend the most appropriate modifications of patient‐specific treatment plans based on efficacy, adverse effects, and follow‐up assessment.
• Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with lower respiratory tract infections. 

HIV Infection and AIDS
ACPE #: 0204-9999-23-969-H02-P

• Assess pharmacotherapies for HIV‐infection and AIDS, including opportunistic infections.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• List recommended immunizations and screening guidelines for patients with HIV.
• Recommend modifications of patient‐specific treatment plans based on efficacy, drug interactions, immunologic or virologic response, and adverse effects.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results related to HIV infection.
• Evaluate a plan to facilitate transitions of care. 

Infections of Reproductive Organs and Sexually Transmitted Diseases
ACPE #: 0204-9999-23-970-H01-P

• Assess pharmacotherapies for infections of reproductive organs and sexually transmitted diseases.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Identify recommended screening guidelines for sexually‐transmitted diseases.
• Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
• Summarize key considerations in effective patient and caregiver education and counseling techniques. 

Opportunistic Infections in Immunocompromised Patients
ACPE #: 0204-9999-23-971-H01-P

• Assess the advantages and disadvantages of pharmacotherapies for opportunistic infections in immunocompromised patients, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information and best available evidence.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
• Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects.
• Identify preventative therapies in immunocompromised patients. 

Gastrointestinal and Intra-abdominal Infections
ACPE #: 0204-9999-23-972-H01-P

• Assess pharmacotherapies for gastrointestinal and intra‐abdominal infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
• Recommend modifications of patient‐specific treatment plans based on efficacy, immunologic response, and adverse effects. 

Viral Hepatitis
ACPE #: 0204-9999-23-973-H01-P

• Assess pharmacotherapies for viral hepatitis, including relevant pharmacology and spectrum of activity.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, virus and genotype, and best available evidence.
• Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
• Recommend modifications of patient‐specific treatment plans based on efficacy, adverse effects, and drug interactions.
• Summarize key considerations in effective patient and caregiver education and counseling techniques.
• Identify screening guidelines and preventive therapies for viral hepatitis. 

Tuberculosis and Other Mycobacterial Infections
ACPE #: 0204-9999-23-974-H01-P

• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient- and disease-specific information, antibiogram data, and best available evidence.
• Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
• Recommend modifications of patient-specific treatment plans based on efficacy, adverse effects, and drug interactions.
• Outline key considerations in effective patient and caregiver education and counseling techniques.
• Identify screening guidelines and preventive therapies for tuberculosis and other mycobacterial infections. 

Cardiovascular Infections
ACPE #: 0204-9999-23-975-H01-P

• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Identify drug‐related problems associated with the therapeutic plan.
• Recommend appropriate modifications of patient‐specific pharmacotherapeutic plans based on efficacy and adverse effects.
• Interpret biomedical literature with regard to study design and methodology, significance of reported data and conclusions, limitations, and applicability of study results to patients with cardiovascular infections. 

Urinary Tract Infections
ACPE #: 0204-9999-23-976-H01-P

• Assess pharmacotherapies for urinary tract infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Interpret signs, symptoms, laboratory and other relevant diagnostic test results.
• Identify infectious diseases for which notification of the Centers for Disease Control and Prevention is required. 

Statistics, Evidence-based Medicine, and Research Design
ACPE #: 0204-9999-23-940-H04-P

• Given an excerpt from a study:
  • Evaluate quality and appropriateness of the excerpt, with specific attention to:
    • study design,
    • statistical analysis,
    • internal/external validity,
    • source of bias/confounders,
    • quality of conclusions,
    • interpretation of graphs.
• Explain why a statistical test is appropriate or not appropriate, based on the sample distribution, data type, and study design.
• Interpret clinical and statistical significance for results from commonly used statistical tests.
• Explain the strengths and limitations of different types of measures of central tendency (mean, median, and mode) and data spread (standard deviation, standard error of the mean, range, and interquartile range).
• Evaluate odds ratio, risk/incidence rate, relative risk, number needed to treat, number needed to harm, and other risk estimates.
• Assess whether the study applies to a specified patient population. 

Bone and Joint Infections and Skin and Soft Tissue Infections
ACPE #: 0204-9999-23-977-H01-P

• Assess the advantages and disadvantages of pharmacotherapies for bone and joint infections and skin and soft tissue infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Identify drug‐related problems associated with the therapeutic plan.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
• Recommend modifications of patient‐specific pharmacotherapeutic plans based on efficacy and adverse effects.
• Describe the etiology, diagnosis, and treatment of acute bacterial osteomyelitis and septic arthritis in pediatric patients. 

Central Nervous System Infections
ACPE #: 0204-9999-23-978-H01-P

• Assess pharmacotherapies for central nervous system infections, including antimicrobial spectrum of activity, pharmacokinetics, and pharmacodynamics.
• Select the most appropriate pharmacotherapeutic plan and monitoring based on patient‐ and disease-specific information, antibiogram data, and best available evidence.
• Interpret signs, symptoms, and laboratory and other relevant diagnostic test results.
• Identify preventive therapies for central nervous system infections. 

Clinical Microbiology
ACPE #: 0204-9999-23-979-H01-P

• Explain the mechanisms of antimicrobial resistance among various pathogens.
• Identify basic microbiology laboratory procedures.
• Interpret laboratory and other diagnostic test results relevant to the diagnosis, management, and monitoring of patients with infectious diseases.
• Evaluate biomedical literature with regard to study design and methodology specific to infectious diseases.

Full faculty bios

Eric Egelund, PharmD, PhD, AAHIVE
Clinical Assistant Professor
University of Florida
Jacksonville, Florida 

Kevin W. Garey, PharmD, MS, FASHP, FIDSA*
Professor and Chair
University of Houston College of Pharmacy
Houston, Texas 

Julie Harting, PharmD, BCIDP
Associate Professor / Clinical Pharmacist Specialist, Infectious Disease
Sullivan University College of Pharmacy and Health Sciences / University of Louisville Hospital
Louisville, Kentucky 

Angela Huang, PharmD, BCIDP
Clinical Pharmacy Manager HonorHealth
John C. Lincoln Medical Center
Phoenix, Arizona 

David Koren, PharmD, MPH, BCPS, AAHIVP
Clinical Pharmacist Specialist - Infectious Diseases / Adjunct Assistant Clinical Professor
Temple University Health System / Lewis Katz School of Medicine at Temple University
Philadelphia, Pennsylvania 

Jerika Lam, PharmD, APh, AAHIVP, FCSHP*
Associate Professor of Pharmacy Practice
Chapman University School of Pharmacy
Irvine, California 

J. Nicholas O'Donnell, PharmD, MSc, BCPS
Associate Professor
Albany College of Pharmacy and Health Sciences
Albany, New York 

Natasha Pettit, PharmD, BCPS, BCIDP
Pharmacy Director of ASP and Pharmacy Clinical Coordinator, ASP/ID
University of Chicago Medicine
Chicago, Illinois 

Jessica Robinson, PharmD, BCPS, BCIDP*
Associate Professor / Associate Director of Antimicrobial Stewardship
University of Charleston School of Pharmacy / Charleston Area Medical Center
Charleston, West Virginia 

Lucas T. Schulz, PharmD, BCIDP
Manager of Pharmacy Practice Advancement and Experiential Education
Manager of Infectious Diseases and Transplant Service Line
Clinical Associate Professor
University of Wisconsin Health/University of Wisconsin School of Pharmacy
Madison, Wisconsin 

Kayla R. Stover, PharmD, BCIDP, BCPS, FCCP, FIDSA*
Associate Professor of Pharmacy Practice
University of Mississippi School of Pharmacy
Jackson, Mississippi 

Trang Trinh, PharmD, MPH, BCIDP, BCPS
Assistant Professor of Clinical Pharmacy
University of California, San Francisco School of Pharmacy
San Francisco, California 

Nancy N. Vuong, PharmD, MBIOT, BCPS, BCIDP
Clinical Pharmacy Specialist, Infectious Diseases
The University of Texas MD Anderson Cancer Center
Houston, Texas 

Wenjing Wei, PharmD, BCIDP
Infectious Diseases Clinical Pharmacist
Parkland Hospital
Dallas, Texas 

Marylee Worley Tailor, PharmD, BCIDP
Assistant Professor
Nova Southeastern University College of Pharmacy
Fort Lauderdale, Florida

*Content matter experts

Kristi N. Hofer, PharmD
Susan R. Dombrowski, MS, RPh 

Hakeem Abayomi, PharmD, BS, BCPS, BCPPS, BCIDP, BCCCP
Jill Argotsinger, PharmD, BCIDP
Caren Azurin, PharmD, BCPS, BCIDP
Linette Beers, PharmD, BCPS, BCCCP, BCIDP
Andrea Beshalske, PharmD, BCIDP
Hita Bhagat, PharmD, BCPS, BCIDP, AAHIVP
Lynn Chan, PharmD, BCIDP
Anthony Chiang, PharmD, BCIDP
Whitney Cook, PharmD, BCIDP
Mandelin Cooper, PharmD, BCPS, BCIDP
Marco Custodio, PharmD, BCIDP, AAHIVP
Lydia D'Agostino, PharmD, BCIDP
Melissa Danek, PharmD, BCPS, BCIDP
Mei Qin Dong, PharmD, BCPS, BCIDP
Jessica Foley, PharmD, BCIDP
Mercedes Fraga, PharmD, BCPS, BCCCP, BCIDPCaroline Gres
ham, PharmD, BCIDP, BCPS
Laila Hasham, PharmD
Melanie Hyte, PharmD, BCIDP
Judy Ikwuagwu, BS, PharmD, BCPS, BCIDP
Caroline Jozefczyk, PharmD, BCIDP
Brett Keskes, PharmD, BCIDP
Madeline King, PharmD, BCIDP
Jeffery Laux, PharmD, BCIDP
Thy Le, PharmD, BCIDP
Jamie Legaspi, PharmD, BCIDP
Adrienne Ma, PharmD, BCIDP
Neha Manchandia, PharmD, BCIDP
Kassandra Marsh, PharmD
Michael McAlister, PharmD, BCIDP
James McCracken-Goncalves, PharmD
Kelley Merrick, PharmD, PhC, BCIDP
Heidi Michaels, PharmD, BCPS, BCCCP, BCIDP
Jessica Miller, PharmD, BCIDP
Yuumi Miyazawa, PharmD, BCIDP
LeAnne Moore, PharmD, BCPS, BCIDP
Lee Nguyen, PharmD, APh, BCPS, BCIDP
Lauren Puckett, PharmD, BCIDP
Alanna Rufe, PharmD, BCIDP
Jacob Schwarz, PharmD, MBA, BCIDP, BCCCP, BCPS, FAzPA
Stephanie Shulder, PharmD, BCIDP
Andrea Simon, PharmD, BCIDP
Mitchell Snyder, PharmD, BCIDP
Jen Sparks, PharmD, BCPS, BCIDP
Jessica Thompson, PharmD, BCPS, BCIDP
Meredith Todd, PharmD, BCPS, BCIDP
Orbie (Obioma) Ubaka , PharmD, BCPS, BCIDP
Mary Ullman, PharmD, BCPS, BCIDP
Mollie VanNatta, PharmD, BCPS, BCIDP
Agnes Vitarini, PharmD, BCPS, BCIDP, BCGP
Marissa Walsh, PharmD, BCPS, BCIDP, DPLA
Solomon Alexander Winans, PharmD, BCIDP
Arsheena Yassin, PharmD, BCIDP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.

The following persons in control of this activity’s content have relevant financial relationships:

• Kevin Garey:  Research grant: Seres Health, Paratek Pharmaceuticals
• Kayla Stover: Advisory board: Cidara Therapeutics, Inc.
• David Koren:  Speakers bureau, Independent consultant: Gilead
• Lucas Schulz: Research grant: Merck

All other persons in control of content do not have any relevant financial relationships with an ineligible company. 

As required by the Standards of Integrity and Independence in Accredited Continuing Education, all relevant financial relationships have been mitigated prior to the CPE activity.

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity. 

ASHP and ACCP collaborate on infectious diseases activities.